PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
21238428-1	2011	Recombinant human interleukin-11 (rhIL-11) has been shown to increase platelet counts in animals and humans and is the only drug approved for its use in chemotherapy-induced thrombocytopenia (CIT).	cit	192-195	interleukin 11	Homo sapiens	18-32
18313196-2	2008	The two chlorinated substances CIT and DCOIT significantly decreased the amount of total cellular glutathione (GSx) in a dose and time dependent manner.	cit	31-34	ATP binding cassette subfamily C member 1	Homo sapiens	111-114
18986840-2	2009	The CIT regimen, represented by recombinant IFNgamma, anti-alpha crystalline monoclonal IgA antibody and IL-4 neutralizing polyclonal antibody, reduced the 8-week relapse of viable bacterial counts in the lungs most significantly, when CIT was inoculated during the 5th week post infection, i.e. during the 3rd week of chemotherapy.	cit	4-7	interferon gamma	Mus musculus	44-52
18986840-2	2009	The CIT regimen, represented by recombinant IFNgamma, anti-alpha crystalline monoclonal IgA antibody and IL-4 neutralizing polyclonal antibody, reduced the 8-week relapse of viable bacterial counts in the lungs most significantly, when CIT was inoculated during the 5th week post infection, i.e. during the 3rd week of chemotherapy.	cit	4-7	interleukin 4	Mus musculus	105-109
17002262-1	2006	Amgen Inc is developing AMG-531, a peptibody that binds to the thrombopoietin receptor Mpl, for the potential treatment of immune thrombocytopenic purpura (ITP), chemotherapy-induced thrombocytopenia (CIT) and thrombocytopenia in myelodysplastic syndrome (MDS).	cit	201-204	MPL proto-oncogene, thrombopoietin receptor	Homo sapiens	87-90
17825933-4	2007	These findings indicate that pictures of faces can be used in a P300 based CIT, and that mere recognition is not sufficient for successful detection of concealed information.	cit	75-78	E1A binding protein p300	Homo sapiens	64-68
17037726-8	2006	RESULTS: After reperfusion, the expression of IRAK-4 were largely depressed in CIT than that of IVT and the control group (P < 0.01), and furthermore, the serum TNF-alpha level, proportion of hepatocyte apoptosis and severity of hepatocyte injury were also lower than the latter.	cit	79-82	interleukin-1 receptor-associated kinase 4	Rattus norvegicus	46-52
16858078-11	2006	The proportion of cTnI methods that demonstrated commutability for the CIT cRM was 45%; for the CI cRM, 39% of methods demonstrated commutability.	cit	71-74	troponin I3, cardiac type	Homo sapiens	18-22
16650410-5	2006	CIT was rapidly inhibited upon addition of an oligonucleotide that competed for the 18S rRNA site complementary to the RPS18C leader and interfered with polysome assembly at the transcript.	cit	0-3	ribosomal protein S18	Triticum aestivum	119-124
12804041-1	2003	Chemoimmunotherapy (CIT) with interleukin-2, interferon-alpha2a, and 5-fluorouracil is an accepted treatment option of metastatic renal cell carcinoma (mRCC).	cit	20-23	interleukin 2	Homo sapiens	30-43
12804041-1	2003	Chemoimmunotherapy (CIT) with interleukin-2, interferon-alpha2a, and 5-fluorouracil is an accepted treatment option of metastatic renal cell carcinoma (mRCC).	cit	20-23	interferon alpha 2	Homo sapiens	45-63
10528215-4	1999	Similarly, E-selectin ligand is preferentially expressed on CD4+ T cells infiltrating the skin (24 +/- 2%), but only on very few CD4+ T cells infiltrating the colon (CIT; 1.3 +/- 0.8%).	cit	166-169	E-selectin	Sus scrofa	11-21
10528215-7	1999	Furthermore, CIT depleted of cells expressing functional P-selectin ligand were able to induce colitis upon transfer, suggesting that induction of colitis in this model may be independent of E- and P-selectin.	cit	13-16	selectin P	Sus scrofa	57-67
10490784-9	1999	They also indicate that the impaired CIT sometimes observed returns to normal after weight reduction suggesting that it is secondary to a decrease in glucose uptake induced by obesity-associated insulin resistance.	cit	37-40	insulin	Homo sapiens	195-202
1954811-10	1991	CONCLUSIONS: Glycemic control improved with both methods of insulin treated patients achieved satisfactory glycemic control (HbA1 less than 50 mmol hydroxymethylfurfural/mol Hb), whereas only 3 of 10 CIT-treated patients achieved this CSII.	cit	200-203	insulin	Homo sapiens	60-67
10366978-4	1999	RESULTS: Compared with that in HST, the expression of T beta R I HT was significantly lower than in HST and CIT (P < 0.01).	cit	108-111	transforming growth factor beta receptor 1	Homo sapiens	54-64
7530621-6	1994	Diabetic patients with conventional insulin therapy (CIT; n = 12) had low IGF-1 (0.57 +/- 0.07 U/ml) compared with patients with continuous subcutaneous insulin infusion (CSII; n = 12; 0.75 +/- 0.08 U/ml; P < 0.05) and intraportal insulin infusion (IPII; n = 12; 1.07 +/- 10.05 U/ml; P < 0.05).	cit	53-56	insulin	Homo sapiens	36-43
7530621-6	1994	Diabetic patients with conventional insulin therapy (CIT; n = 12) had low IGF-1 (0.57 +/- 0.07 U/ml) compared with patients with continuous subcutaneous insulin infusion (CSII; n = 12; 0.75 +/- 0.08 U/ml; P < 0.05) and intraportal insulin infusion (IPII; n = 12; 1.07 +/- 10.05 U/ml; P < 0.05).	cit	53-56	insulin like growth factor 1	Homo sapiens	74-79
8514459-1	1993	We had earlier shown that tumor-bearing results in an inactivation of IL-2-dependent effector cells by host macrophage-derived PGE2, and that chronic indomethacin therapy (CIT) aimed at blocking prostaglandin synthesis, combined with multiple rounds of IL-2, can cure experimental metastases of a variety of tumors in mice.	cit	172-175	interleukin 2	Mus musculus	253-257
3300667-8	1987	Following the shift from CIT to CSII, HDL2-chol rose further (P less than 0.05), whereas HDL3-chol remained unchanged.	cit	25-28	junctophilin 3	Homo sapiens	38-42
2337895-5	1990	CIT alone retarded tumor growth and stimulated cytotoxic activity in splenocytes as well as tumor-infiltrating lymphocytes against YAC-1 lymphoma and EAT targets but resulted in no cure.	cit	0-3	ADP-ribosyltransferase 1	Mus musculus	131-136
2090199-12	1990	CIT + 3 rounds of IL-2 reduced the median colony counts from 40 to 0 and improved the survival from a median of 66 (control) to 120 days (40% surviving 260 + days).	cit	0-3	interleukin 2	Mus musculus	18-22
2090199-13	1990	CIT + four or five rounds of IL-2 caused long-term (260 + days) survival of 80% mice, most surviving 400 + days.	cit	0-3	interleukin 2	Mus musculus	29-33
34672825-7	2021	For HER2+ patients, use of CIT treatment downtrended with progression of pathological stage, from 70.1% (stage I) to 58.1% (stage III).	cit	27-30	erb-b2 receptor tyrosine kinase 2	Homo sapiens	4-8
3318256-4	1987	We obtained better blood glucose control both by CSII and CBII than by CIT, with significant reduction of HbA1 values.	cit	71-74	hemoglobin subunit alpha 1	Homo sapiens	106-110
3300667-9	1987	When CSII was changed to CIT, the HDL3-chol level decreased (P less than 0.02), but HDL2-chol remained constant.	cit	25-28	HDL3	Homo sapiens	34-38
32638524-4	2021	To address this, we investigated effects of adolescent chronic intermittent toluene (CIT) inhalation on gene expression and DNA methylation profiles within the rat medial prefrontal cortex (mPFC), which undergoes maturation throughout adolescence and has been implicated in toluene-induced cognitive deficits.	cit	85-88	complement factor properdin	Mus musculus	190-194
4075944-7	1985	We conclude that elevated GFR values can be reduced toward normal level by insulin pump treatment for 1 yr. Retinal morphology was found to deteriorate in four of 12 CIT subjects and in three of 12 CSII subjects.	cit	166-169	insulin	Homo sapiens	75-82
968323-0	1976	[Evaluation of serum alpha-1-antitrypsin using trypsin inhibition capacity (CIT).	cit	76-79	serpin family A member 1	Homo sapiens	21-40
32638524-6	2021	We demonstrate for the first time that adolescent CIT exposure results in dynamic regulation of the mPFC transcriptome likely relating to acute inflammatory responses and persistent deficits in synaptic plasticity.	cit	50-53	complement factor properdin	Mus musculus	100-104
32404734-13	2020	CX3CR1+CD8+ therapy-responsive T-cells can be potentially used for monitoring disease response to CIT.	cit	98-101	C-X3-C motif chemokine receptor 1	Homo sapiens	0-6
33212483-8	2021	Furthermore, analysis of the association between NLRP3 inflammasome and CIT response using six CIT response datasets revealed the predictive value of NLRP3 inflammasome for immunotherapy response of patients in diverse cancers.	cit	72-75	NLR family pyrin domain containing 3	Homo sapiens	49-54
33212483-8	2021	Furthermore, analysis of the association between NLRP3 inflammasome and CIT response using six CIT response datasets revealed the predictive value of NLRP3 inflammasome for immunotherapy response of patients in diverse cancers.	cit	72-75	NLR family pyrin domain containing 3	Homo sapiens	150-155
32404734-13	2020	CX3CR1+CD8+ therapy-responsive T-cells can be potentially used for monitoring disease response to CIT.	cit	98-101	CD8a molecule	Homo sapiens	7-10
32185224-3	2020	Here, we reported that the citron Rho-interacting serine/threonine kinase (CIT) promotes the HIF1a-CypA signaling and growth of PDAC cells.	cit	75-78	citron rho-interacting serine/threonine kinase	Homo sapiens	27-73
32226027-4	2020	CIT resulted in a dramatic expansion of cytotoxic CD4+ and CD8+ T cells and a subsequent reduction in viral loads.	cit	0-3	CD4 antigen	Mus musculus	50-53
32226027-4	2020	CIT resulted in a dramatic expansion of cytotoxic CD4+ and CD8+ T cells and a subsequent reduction in viral loads.	cit	0-3	CD8a molecule	Homo sapiens	59-62
32185224-3	2020	Here, we reported that the citron Rho-interacting serine/threonine kinase (CIT) promotes the HIF1a-CypA signaling and growth of PDAC cells.	cit	75-78	hypoxia inducible factor 1 subunit alpha	Homo sapiens	93-98
32185224-3	2020	Here, we reported that the citron Rho-interacting serine/threonine kinase (CIT) promotes the HIF1a-CypA signaling and growth of PDAC cells.	cit	75-78	peptidylprolyl isomerase A	Homo sapiens	99-103
32185224-6	2020	The knockdown of CIT in PDAC cells reduced the expression of CypA while overexpression of CIT promoted the expression of CypA.	cit	17-20	peptidylprolyl isomerase A	Homo sapiens	61-65
32185224-6	2020	The knockdown of CIT in PDAC cells reduced the expression of CypA while overexpression of CIT promoted the expression of CypA.	cit	90-93	peptidylprolyl isomerase A	Homo sapiens	121-125
32185224-7	2020	We observed that the effects of CIT on the expression of CypA relied on the transcriptional factor HIF1a, which was previously reported to transcriptionally activate the expression of CypA in PDAC cells.	cit	32-35	peptidylprolyl isomerase A	Homo sapiens	57-61
32185224-7	2020	We observed that the effects of CIT on the expression of CypA relied on the transcriptional factor HIF1a, which was previously reported to transcriptionally activate the expression of CypA in PDAC cells.	cit	32-35	hypoxia inducible factor 1 subunit alpha	Homo sapiens	99-104
32185224-7	2020	We observed that the effects of CIT on the expression of CypA relied on the transcriptional factor HIF1a, which was previously reported to transcriptionally activate the expression of CypA in PDAC cells.	cit	32-35	peptidylprolyl isomerase A	Homo sapiens	184-188
32185224-8	2020	Furthermore, the effects of CIT on apoptosis, cell cycle, proliferation, and colony formation of PDAC cells relied on its role in the regulation of CypA expression.	cit	28-31	peptidylprolyl isomerase A	Homo sapiens	148-152
32185224-9	2020	Collectively, our data showed that CIT promoted the activation of HIF1-CypA signaling and enhanced the growth of PDAC cells.	cit	35-38	hypoxia inducible factor 1 subunit alpha	Homo sapiens	66-70
32185224-9	2020	Collectively, our data showed that CIT promoted the activation of HIF1-CypA signaling and enhanced the growth of PDAC cells.	cit	35-38	peptidylprolyl isomerase A	Homo sapiens	71-75
31354046-1	2019	We investigate if PD-L1 expression and other clinical characteristics predict chemoimmunotherapy (CIT) benefits versus chemotherapy in advanced non-small-cell lung cancer.	cit	98-101	CD274 molecule	Homo sapiens	18-23
31434681-1	2019	Chronic lymphocytic leukemia patients with mutated immunoglobulin heavy-chain genes (IGHV-M), particularly those lacking poor-risk genomic lesions, often respond well to chemoimmunotherapy (CIT).	cit	190-193	immunoglobulin heavy variable 3-69-1 (pseudogene)	Homo sapiens	85-89
30746747-5	2019	CIT training resulted in reductions in stigmatic attitudes with seven large effect sizes (ranging from eta2  = .24 to .59) across the two measures.	cit	0-3	DNA polymerase iota	Homo sapiens	103-107
31354046-6	2019	PD-L1 status is predictive of CIT benefit and may assist patient selection and design of future trials.	cit	30-33	CD274 molecule	Homo sapiens	0-5
31052277-7	2019	Daily caloric intake was significantly higher in the target feeding than in the permissive underfeeding groups (P-value < 0.01), and the daily insulin dose was significantly higher in the IIT than in the CIT groups (P-value < 0.01).	cit	207-210	insulin	Homo sapiens	146-153
30419350-5	2019	Programmed cell death ligand-1 (PD-L1), which is a validated biomarker in non-small cell lung cancer (NSCLC), is often also used to select patients for CIT in the context of gastroesophageal cancer, although this marker has not been validated for this purpose.	cit	152-155	CD274 molecule	Homo sapiens	0-30
30764783-5	2019	CIT was identified based on: diagnosis code for thrombocytopenia or bleeding; procedure code for platelet transfusion or bleeding control; or drug code for thrombopoietin-receptor agonist.	cit	0-3	MPL proto-oncogene, thrombopoietin receptor	Homo sapiens	156-179
30419350-5	2019	Programmed cell death ligand-1 (PD-L1), which is a validated biomarker in non-small cell lung cancer (NSCLC), is often also used to select patients for CIT in the context of gastroesophageal cancer, although this marker has not been validated for this purpose.	cit	152-155	CD274 molecule	Homo sapiens	32-37
30419350-7	2019	This review discusses the value of PD-L1 in selecting patients for CIT in esophageal and gastric cancer.	cit	67-70	CD274 molecule	Homo sapiens	35-40
29997221-2	2018	With the availability of pathway inhibitors (PIs), such as kinase inhibitors and BCL2 antagonists, the outlook of CIT-resistant patients has dramatically improved.	cit	114-117	BCL2 apoptosis regulator	Homo sapiens	81-85
30563320-3	2019	Herein, we report a hypoxia-responsive mesoporous silica nanocarrier (denoted as CAGE) for an enhanced CIT assisted by photodynamic therapy (PDT).	cit	103-106	DEAD-box helicase 53	Homo sapiens	81-85
30293399-3	2018	The main treatments of CIT include transfusion of platelets, recombinant human thrombopoietin (rhTPO), and recombinant human interleukin-11 (rhIL-11).	cit	23-26	thrombopoietin	Homo sapiens	79-93
30293399-3	2018	The main treatments of CIT include transfusion of platelets, recombinant human thrombopoietin (rhTPO), and recombinant human interleukin-11 (rhIL-11).	cit	23-26	interleukin 11	Homo sapiens	125-139
30223836-10	2018	The application of the IBV nsp5 protein microarray showed that the positive rate of the CIT was 96.77%, that of the nsp5 ELISA was 91.40%, and that of the RDT was 90.32%.	cit	88-91	sperm antigen with calponin homology and coiled-coil domains 1	Homo sapiens	27-31
30045972-16	2018	Finally, anti-cit-CRT Abs were preferentially detected in ACPA+ versus ACPA- RA sera.	cit	14-17	proteinase 3	Homo sapiens	58-62
30045972-16	2018	Finally, anti-cit-CRT Abs were preferentially detected in ACPA+ versus ACPA- RA sera.	cit	14-17	proteinase 3	Homo sapiens	71-75
29997221-4	2018	CLL high-risk-I, CIT-resistant is defined by clinically CIT-resistant disease with TP53 aberrations, but fully responsive to PI.	cit	17-20	tumor protein p53	Homo sapiens	83-87
29997221-4	2018	CLL high-risk-I, CIT-resistant is defined by clinically CIT-resistant disease with TP53 aberrations, but fully responsive to PI.	cit	56-59	tumor protein p53	Homo sapiens	83-87
30280609-5	2018	The IRE1alpha-XBP1 branch was activated at reperfusion only if CIT extended beyond 8 h, and had a dual role on cell fate - deleterious through IRE1"s RNase activity and beneficial through IRE1alpha other roles.	cit	63-66	endoplasmic reticulum to nucleus signaling 1	Homo sapiens	4-8
30116746-3	2018	T1DM patients who partake in high-intensity aerobic training (AThigh) to reduce CVD often utilize conventional insulin therapy (CIT; 9-15 mmol/L) to offset the risk of hypoglycemia.	cit	128-131	insulin	Homo sapiens	111-118
29083483-6	2018	These findings suggest that collaborative encoding of crime-related information impacts the efficiency of the P300 index, and that the P300-based CIT is not applicable when used to identify collaborative crime perpetrators.	cit	146-149	E1A binding protein p300	Homo sapiens	135-139
29375446-8	2017	After the antecedent emotional experience, the P300-based CIT was conducted.	cit	58-61	E1A binding protein p300	Homo sapiens	47-51
29375446-11	2017	These results support the notion that emotional arousal influences the P300 in the CIT paradigm.	cit	83-86	E1A binding protein p300	Homo sapiens	71-75
30280609-5	2018	The IRE1alpha-XBP1 branch was activated at reperfusion only if CIT extended beyond 8 h, and had a dual role on cell fate - deleterious through IRE1"s RNase activity and beneficial through IRE1alpha other roles.	cit	63-66	endoplasmic reticulum to nucleus signaling 1	Homo sapiens	188-197
29480432-5	2018	Recent updates in CIT include that immunoglobulin heavy chain variable (IGHV) gene mutation status is strongly predictive of response to CIT.	cit	18-21	immunoglobulin heavy variable 3-69-1 (pseudogene)	Homo sapiens	35-77
29480432-5	2018	Recent updates in CIT include that immunoglobulin heavy chain variable (IGHV) gene mutation status is strongly predictive of response to CIT.	cit	137-140	immunoglobulin heavy variable 3-69-1 (pseudogene)	Homo sapiens	35-77
30280609-5	2018	The IRE1alpha-XBP1 branch was activated at reperfusion only if CIT extended beyond 8 h, and had a dual role on cell fate - deleterious through IRE1"s RNase activity and beneficial through IRE1alpha other roles.	cit	63-66	endoplasmic reticulum to nucleus signaling 1	Homo sapiens	4-13
30280609-6	2018	Finally, the pro-apoptotic factor CHOP was a common target of both ATF6 and IRE1alpha pathways and was associated with elongated CIT and increased cell death.	cit	129-132	DNA damage inducible transcript 3	Homo sapiens	34-38
28450306-7	2017	Importantly, we found that low doses of IL-9 efficiently prevented chemotherapy-induced thrombocytopenia (CIT) and accelerated platelet recovery after CIT.	cit	106-109	interleukin 9	Mus musculus	40-44
30280609-6	2018	Finally, the pro-apoptotic factor CHOP was a common target of both ATF6 and IRE1alpha pathways and was associated with elongated CIT and increased cell death.	cit	129-132	activating transcription factor 6	Homo sapiens	67-71
30280609-6	2018	Finally, the pro-apoptotic factor CHOP was a common target of both ATF6 and IRE1alpha pathways and was associated with elongated CIT and increased cell death.	cit	129-132	endoplasmic reticulum to nucleus signaling 1	Homo sapiens	76-85
30280609-5	2018	The IRE1alpha-XBP1 branch was activated at reperfusion only if CIT extended beyond 8 h, and had a dual role on cell fate - deleterious through IRE1"s RNase activity and beneficial through IRE1alpha other roles.	cit	63-66	X-box binding protein 1	Homo sapiens	14-18
28589701-2	2017	One such predictive biomarker is the mutational status of the variable region of the immunoglobulin heavy chain (IGHV) gene, which is a powerful predictor of duration of response and overall survival with chemoimmunotherapy (CIT).	cit	225-228	immunoglobulin heavy variable 3/OR16-7 (pseudogene)	Homo sapiens	85-111
28589701-2	2017	One such predictive biomarker is the mutational status of the variable region of the immunoglobulin heavy chain (IGHV) gene, which is a powerful predictor of duration of response and overall survival with chemoimmunotherapy (CIT).	cit	225-228	immunoglobulin heavy variable 3/OR16-7 (pseudogene)	Homo sapiens	113-117
28450306-7	2017	Importantly, we found that low doses of IL-9 efficiently prevented chemotherapy-induced thrombocytopenia (CIT) and accelerated platelet recovery after CIT.	cit	151-154	interleukin 9	Mus musculus	40-44
28450306-8	2017	These data indicate that IL-9 is an essential regulator of megakaryopoiesis and a promising therapeutic agent for treatment of thrombocytopenia such as CIT.	cit	152-155	interleukin 9	Mus musculus	25-29
27420293-11	2016	CONCLUSION: An increased CIMT by aging was mainly due to increased CMT rather than CIT in asymptomatic adults.	cit	83-86	CIMT	Homo sapiens	25-29
27906052-11	2016	However, association was observed between the PTPN22 risk allele and positivity to cit-Fib alpha-35 and cit-Fib alpha-263,271.	cit	83-86	protein tyrosine phosphatase non-receptor type 22	Homo sapiens	46-52
27906052-11	2016	However, association was observed between the PTPN22 risk allele and positivity to cit-Fib alpha-35 and cit-Fib alpha-263,271.	cit	83-86	fibrinogen beta chain	Homo sapiens	87-90
27322064-9	2016	Importantly, the Causal Inference Test (CIT) demonstrates how genetic variants mediate their effects on metabolic traits (e.g. BMI, cholesterol, high-density lipoprotein (HDL), hemoglobin A1c (HbA1c) and homeostatic model assessment of insulin resistance (HOMA-IR)) via altered DNA methylation in human adipose tissue.	cit	40-43	insulin	Homo sapiens	236-243
27055777-14	2016	Some new IgG- and IgA-ACPA, generally to different Cit-antigens however, arose at Relapse in 4 patients.	cit	51-54	proteinase 3	Homo sapiens	22-26
26236025-7	2015	In CIT-exposed rats binding to N-methyl-D-aspartate (NMDA) receptors containing the GluN2B subunit, as determined using [(3)H]-ifenprodil, was decreased in a concentration-related manner in the caudal cingulate cortex, dorsal striatum and accumbens; however, this was not associated with changes in GluN2B protein expression.	cit	3-6	glutamate ionotropic receptor NMDA type subunit 2B	Rattus norvegicus	84-90
25825261-2	2016	We evaluated the risk of DSWI and other clinical outcomes between continuous insulin infusion therapy (CIT) and insulin sliding scale therapy (IST) in a cohort of DM patients who underwent CABG with BIMA.	cit	103-106	insulin	Homo sapiens	77-84
26925632-1	2016	OBJECTIVE: to investigate the effect and side effects of recombinant human interleukin - 11 (rhIL - 11, in Chinese Juheli, produced by Qi Lu Biotechnology CO., LTD) in the second prevention of chemotherapy induced thrombocytopenia (CIT).	cit	232-235	interleukin 11	Homo sapiens	75-91
26236025-7	2015	In CIT-exposed rats binding to N-methyl-D-aspartate (NMDA) receptors containing the GluN2B subunit, as determined using [(3)H]-ifenprodil, was decreased in a concentration-related manner in the caudal cingulate cortex, dorsal striatum and accumbens; however, this was not associated with changes in GluN2B protein expression.	cit	3-6	glutamate ionotropic receptor NMDA type subunit 2B	Rattus norvegicus	299-305
25838088-9	2015	mPIS values of subjects requiring continuous inhalation therapy (CIT) with isoproterenol in addition to systemic steroids were significantly higher than the values of those without CIT (12.0 +- 0.5 and 9.3 +- 0.2, respectively, p < 0.001).	cit	65-68	CDP-diacylglycerol--inositol 3-phosphatidyltransferase (phosphatidylinositol synthase)	Mus musculus	0-4
26337028-5	2015	Serum RANKL (total RANKL), ACPA (anti-CCP2) and ACPA specificities (anti-citrullinated (cit)-vimentin, anti-cit-enolase and anti-cit-fibrinogen) were determined by enzyme-linked immunosorbent assay (ELISA).	cit	60-63	TNF superfamily member 11	Homo sapiens	6-11
26337028-5	2015	Serum RANKL (total RANKL), ACPA (anti-CCP2) and ACPA specificities (anti-citrullinated (cit)-vimentin, anti-cit-enolase and anti-cit-fibrinogen) were determined by enzyme-linked immunosorbent assay (ELISA).	cit	60-63	proteinase 3	Homo sapiens	48-52
26337028-11	2015	Among ACPA specificites, anti-cit-vimentin (amino acids 60-75) was associated with higher RANKL concentration and higher prevalence of bone erosion (p <0.05).	cit	18-21	proteinase 3	Homo sapiens	6-10
26337028-11	2015	Among ACPA specificites, anti-cit-vimentin (amino acids 60-75) was associated with higher RANKL concentration and higher prevalence of bone erosion (p <0.05).	cit	18-21	vimentin	Homo sapiens	34-42
25899003-5	2015	We reproducibly associate higher expression of the ligand-receptor axis of TFF2 and CXCR4 with BRAF V600E-mutant colon cancer (P = 3.0 x 10(-3) and 0.077, respectively for TCGA; P = 3.0 x 10(-8) and 5.1 x 10(-7) for CIT).	cit	216-219	trefoil factor 2	Homo sapiens	75-79
26337028-13	2015	CONCLUSIONS: RANKL was elevated in ACPA-positive and in anti-cit-vimentin-positive patients with early untreated RA and associated with bone erosions.	cit	61-64	TNF superfamily member 11	Homo sapiens	13-18
26337028-13	2015	CONCLUSIONS: RANKL was elevated in ACPA-positive and in anti-cit-vimentin-positive patients with early untreated RA and associated with bone erosions.	cit	61-64	vimentin	Homo sapiens	65-73
25428389-2	2015	In this paper, I discussed the effect of ABO blood group on CIT in patients with stage III colon cancer.	cit	60-63	ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase	Homo sapiens	41-56
25729723-8	2015	CONCLUSIONS: Combined use of the MHT and CIT with PBA and EDTA, for the detection of CPE and MBL-producing Pseudomonas spp., is effective in detecting and characterizing carbapenemases in routine laboratories.	cit	41-44	hypothetical protein	Klebsiella pneumoniae	93-96
25405287-10	2014	In addition, the CIT administration also significantly enhanced the OPG expression, whereas reduced the RANKL expression in femurs according to RT-PCR, western blot assays and immunohistochemical evaluation.	cit	17-20	TNF receptor superfamily member 11B	Rattus norvegicus	68-71
25405287-10	2014	In addition, the CIT administration also significantly enhanced the OPG expression, whereas reduced the RANKL expression in femurs according to RT-PCR, western blot assays and immunohistochemical evaluation.	cit	17-20	TNF superfamily member 11	Rattus norvegicus	104-109
22507801-2	2012	Chemoimmunotherapy (CIT) combining anti-CD20 monoclonal antibodies with purine nucleoside analogs has been a substantial advance for patients with CLL and results in increased response rates, progression-free survival, and overall survival.	cit	20-23	keratin 20	Homo sapiens	40-44
23490488-1	2014	BACKGROUND AND OBJECTIVE: Recent studies in critically ill patients receiving insulin intravenous therapy (IIT) have shown an increased incidence of severe hypoglycemia, while intermittent subcutaneous insulin <<sliding scales>> (conventional insulin therapy [CIT]) is associated with hyperglycemia.	cit	272-275	insulin	Homo sapiens	78-85
23490488-1	2014	BACKGROUND AND OBJECTIVE: Recent studies in critically ill patients receiving insulin intravenous therapy (IIT) have shown an increased incidence of severe hypoglycemia, while intermittent subcutaneous insulin <<sliding scales>> (conventional insulin therapy [CIT]) is associated with hyperglycemia.	cit	272-275	insulin	Homo sapiens	202-209
23490488-1	2014	BACKGROUND AND OBJECTIVE: Recent studies in critically ill patients receiving insulin intravenous therapy (IIT) have shown an increased incidence of severe hypoglycemia, while intermittent subcutaneous insulin <<sliding scales>> (conventional insulin therapy [CIT]) is associated with hyperglycemia.	cit	272-275	insulin	Homo sapiens	202-209
23543349-5	2013	Citrullinated (Cit) and native peptides of Vimentin and Aggrecan were used for stimulating peripheral blood mononuclear cells in 5-day cultures.	cit	0-3	vimentin	Homo sapiens	43-51
23256681-10	2013	EXPERT OPINION: Rituximab, the prototype anti-CD20 mAb, forms the core of CIT in CLL.	cit	74-77	keratin 20	Homo sapiens	46-50
23150685-3	2013	OBJECTIVE: Our objective was to evaluate the effects of mild cold exposure on circulating FGF21 and its relationship with CIT and lipolysis in humans.	cit	122-125	fibroblast growth factor 21	Homo sapiens	90-95
23150685-12	2013	CONCLUSIONS: Mild cold exposure increased circulating FGF21 levels, predicting greater lipolysis and CIT.	cit	101-104	fibroblast growth factor 21	Homo sapiens	54-59
21632816-9	2011	RESULTS: On d 3, C-peptide was more than 10-fold lower (P < 0.0001) in the IIT group than in the CIT group.	cit	100-103	insulin	Homo sapiens	17-26
22114740-5	2012	Using variables of ACS symptoms we estimated the likelihood of ACS based on a CIT to be high at 91% (32), low at 4% (198) and intermediate at 20.5-40% in (71) patients.	cit	78-81	1-aminocyclopropane-1-carboxylate synthase homolog (inactive)	Homo sapiens	63-66
21907557-1	2011	Chrono-impedance technique (CIT) was implemented as a new transduction method for real time measurement of glucose in a biosensor system based in carbon paste (CP)/Ferrocene (FC)/glucose oxidase (GOx).	cit	28-31	hydroxyacid oxidase 1	Homo sapiens	196-199
22071938-2	2011	In the present study, we performed a meta-analysis of literature comparing the efficacy and safety of IIT and conventional insulin therapy (CIT) for critically ill neurologic patients in terms of mortality, infection rate, neurologic outcome, and hypoglycemia.	cit	140-143	insulin	Homo sapiens	123-130
21609374-6	2011	RESULTS: In 22 CDD organ transplants, CIT was a strong predictor of PNF or IC (P = 0.021).	cit	38-41	natriuretic peptide A	Homo sapiens	15-18
21683135-10	2011	In addition, CIT increased CRF-R2 gene expression in the dorsal raphe.	cit	13-16	corticotropin releasing hormone receptor 2	Homo sapiens	27-33
21609374-7	2011	Minimising CIT in CDD organ transplants produced outcomes similar to those in a matched SCD organ transplant cohort at our centre and in SCD organ transplant results nationally (1- and 3-year graft and patient survival rates: 90.9% and 73.3% vs. 77.6% and 69.2% in CDD and SCD grafts, respectively.	cit	11-14	natriuretic peptide A	Homo sapiens	18-21
21609374-7	2011	Minimising CIT in CDD organ transplants produced outcomes similar to those in a matched SCD organ transplant cohort at our centre and in SCD organ transplant results nationally (1- and 3-year graft and patient survival rates: 90.9% and 73.3% vs. 77.6% and 69.2% in CDD and SCD grafts, respectively.	cit	11-14	natriuretic peptide A	Homo sapiens	265-268
21609374-9	2011	CONCLUSIONS: These findings suggest that a targeted effort to minimise CIT might improve outcomes and allow the safer use of CDD organs.	cit	71-74	natriuretic peptide A	Homo sapiens	125-128